MiMedx Group, Inc (NASDAQ:MDXG) Receives Average Recommendation of “Moderate Buy” from Brokerages

MiMedx Group, Inc (NASDAQ:MDXG) has earned an average recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have given a buy recommendation to the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $8.5714.

A number of brokerages have recently issued reports on MDXG. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Craig Hallum upped their price target on shares of MiMedx Group from $6.00 to $8.00 and gave the company a “buy” rating in a research report on Thursday, August 27th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Raymond James Financial set a $8.00 target price on MiMedx Group in a research note on Monday, August 17th. Finally, Weiss Ratings upgraded MiMedx Group from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, August 27th.

MiMedx Group Trading Down 1.7%

Shares of MiMedx Group stock opened at $4.60 on Friday. MiMedx Group has a 1 year low of $3.03 and a 1 year high of $7.97. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79. The firm has a market cap of $670.50 million, a PE ratio of 115.03 and a beta of 1.43. The company has a 50 day simple moving average of $4.31 and a two-hundred day simple moving average of $4.05.

MiMedx Group (NASDAQ:MDXG) last announced its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The firm had revenue of $64.36 million for the quarter, compared to analyst estimates of $63.46 million. Analysts expect that MiMedx Group will post -0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the company. Sunbelt Securities Inc. purchased a new stake in MiMedx Group during the 1st quarter valued at $42,000. E Fund Management Co. Ltd. bought a new position in shares of MiMedx Group during the second quarter valued at about $45,000. Syon Capital LLC purchased a new stake in shares of MiMedx Group during the second quarter worth about $45,000. Legal & General Group Plc purchased a new position in MiMedx Group during the 2nd quarter valued at about $45,000. Finally, Kemnay Advisory Services Inc. purchased a new position in MiMedx Group during the 4th quarter valued at about $48,000. 79.15% of the stock is owned by hedge funds and other institutional investors.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.